Who pays for menopausal hormone therapy (MHT) in Canada, province by province.
Two provinces cover menopausal hormone therapy under their public drug plan. The rest of the country pays through employer benefits, private insurance, or directly at the pharmacy. Here's the honest map, and the cost question worth asking before you start.
Why this page exists.
Cost is one of the quietest reasons women don't start MHT, and one of the loudest reasons they stop. In Canada, what you pay depends almost entirely on which side of a provincial border you live on, which is a frustrating sentence to write in a country with universal healthcare. Manitoba moved first in April 2025, BC followed on March 1, 2026, and the conversation in other provinces is heating up. As of mid-2026, the rest of the map still looks like a patchwork.
This is education only. Coverage rules change. Confirm the current state with your provincial drug-plan website or your pharmacist before you assume anything.
British Columbia
Publicly funded
Free under National Pharmacare (Plan NP) since March 1, 2026.
BC PharmaCare had long listed menopausal hormone therapy, but most people paid until they hit their income-based deductible. Since March 1, 2026, many MHT options (patches, gels, oral estradiol, micronized progesterone) are fully covered under the National Pharmacare plan (Plan NP) for anyone enrolled in MSP, including people still in the MSP wait period. No medication cost, no dispensing fee, and no Special Authority needed for the listed products. You still need a prescription; what changes is the bill. Check the PharmaCare Plan NP benefit list, because not every brand or formulation is on it. BC Women's Hospital, the Women's Health Research Institute, UBC and the BC Women's Health Foundation are also building Western Canada's first dedicated Menopause + Midlife Health Program: a referral-based provincial clinic for complex midlife care, paired with research and clinician training. It's in fundraising and build-out as of 2026, not yet open for general referrals, but it's the closest thing in the country to a publicly-anchored specialist menopause centre.
Manitoba
Publicly funded
Free under the Manitoba Enhanced Pharmacare Program (since April 15, 2025).
Manitoba was actually first to make hormone therapy free at the counter. The Manitoba Enhanced Pharmacare Program (MEPP) launched April 15, 2025 and covers most hormone replacement therapy medications at no cost, alongside birth control, diabetes and HIV medications. You need an active Manitoba Health card and no other plan that already pays 100%. MEPP covers the medication up to the price of the lowest-cost interchangeable product, plus the dispensing fee. A few products are Exception Drug Status, so your prescriber has to send in a prior-approval request first.
Ontario
Partial / age-based
Covered only via OHIP+ (under 25), ODB (65+), or employer plan.
If you're between 25 and 64 with no private drug coverage in Ontario, which is most women in the menopause window, you pay out of pocket or through your employer's benefits. The Ontario Drug Benefit kicks in at 65 and covers most MHT formulations. Ontario Health (Health Quality Ontario) published a Quality Standard for menopause care in 2024, which sets out what good assessment, MHT counselling, and follow-up should look like across the province. It isn't a funding decision, but it gives you something concrete to point at when you're asking a clinician for a fuller conversation. Several patient-advocacy campaigns are also pushing for universal MHT coverage; nothing has passed as of early 2026.
Quebec
Partial / age-based
Covered through RAMQ public drug plan (if you're enrolled).
Quebec's prescription drug regime is unique: every resident must have either employer drug coverage or be enrolled in the RAMQ public plan. Most MHT formulations are on the RAMQ formulary. You'll still owe the standard RAMQ premium and co-pay structure, but it's meaningfully cheaper than fully out-of-pocket.
Alberta
Mostly private / out of pocket
No general public coverage; private/employer or out of pocket.
Alberta covers MHT for seniors (65+) via the Alberta Seniors Benefit and for some recipients of AISH or income support. For working-age women, it's whatever your employer benefits cover. Generic estradiol and micronized progesterone are typically the cheapest cash-pay options.
Saskatchewan
Mostly private / out of pocket
No general public coverage; senior and special-support programs only.
Saskatchewan's drug plan covers MHT for seniors and some special-support categories. Most working-age women pay through employer plans or out of pocket. Costs vary widely by formulation, patches and gels tend to be more expensive than generic oral estradiol.
Nova Scotia, New Brunswick, PEI, Newfoundland & Labrador
Mostly private / out of pocket
Public plans cover seniors and special groups; otherwise out of pocket.
The Atlantic provinces all run senior-focused drug plans (NS Pharmacare, NB Drug Plan, PEI Pharmacare, NL Pharmaceutical Services). For women in the typical menopause window, MHT is usually paid through employer benefits or directly. Some special low-income programs exist; eligibility varies sharply by province.
Yukon, NWT, Nunavut
Partial / age-based
Territorial plans and Non-Insured Health Benefits (NIHB) for First Nations and Inuit.
The territories have their own drug benefit plans with broader public coverage than most provinces. NIHB (federal) covers prescription medications including most MHT for registered First Nations and Inuit residents Canada-wide. Coverage of specific formulations varies, confirm with your local health centre or pharmacist.
Three things worth knowing whatever province you're in.
Generic estradiol and micronized progesterone are dramatically cheaper than branded versions , sometimes 5–10× less. Ask your prescriber to write generic where clinically appropriate, and ask your pharmacist what the cash price is across local pharmacies (Costco often wins, membership not required for the pharmacy counter in most provinces).
Vaginal estrogen is its own line item and is often covered separately from systemic MHT under employer plans. If you've been told "estrogen isn't covered", ask specifically about vaginal estradiol (cream, tablet, or ring), it's a different formulary code.
Compounded "bioidentical" hormones are almost never covered by any provincial plan or most private insurers, because there's no clinical reason to use them over the regulated body-identical options. If a clinic is steering you to compounded creams or pellets, the cost difference compounds too.
Canadian advocacy context
The push for public MHT coverage isn't coming out of nowhere. The Menopause Foundation of Canada's Silence and the Stigma report found that 1 in 2 Canadian women feel unprepared for perimenopause and 95% experience symptoms (an average of seven each). Their Menopause and Work report puts the cost of unmanaged symptoms at $3.5 billion a year and 540,000 lost workdays. Numbers like these are what moved BC and Manitoba, and they're what other provinces are now being asked to answer for.
In June 2026 the Society of Obstetricians and Gynaecologists of Canada (SOGC) went further, calling for menopause care to be free at the front line and for family physicians, nurse practitioners, pharmacists and emergency providers, not just specialists, to be trained to deliver it. They cited a 2024 BC study of 2,100 women aged 39–60: 43.5% had turned to at least one extended health provider to manage menopause symptoms, most commonly massage therapists, naturopaths, mental health professionals, physiotherapists and acupuncturists, almost none of which Medicare covers. 13.2% relied on those providers exclusively because nothing inside the public system was helping. The wait gap isn't in your head, it's in the system.
Going private?
Non-hormonal, and still not covered
Elinzanetant (Lynkuet) was cleared for breast cancer patients in August 2026. No public plan pays for it.
Health Canada first authorized elinzanetant, a non-hormonal treatment for hot flashes and night sweats, in July 2025. In August 2026 it broadened that authorization to cover women taking endocrine therapy for breast cancer, who cannot take hormone therapy and whose symptoms are severe enough that some stop their cancer medication for relief. Bayer's OASIS-4 study followed 395 women aged 18 to 70 over 52 weeks and reported a significant drop in symptoms and fewer sleep disturbances against placebo, with 91.6% choosing to continue for a further two years.
The coverage picture is the familiar one: Bayer has confirmed the drug is not publicly funded anywhere in Canada and has not named a price. If you're in this group, ask your oncology team whether it's clinically appropriate and ask your employer or private plan whether it's on formulary, because for now those are the only two doors. Worth noting that the trial investigator quoted in coverage of the approval discloses paid consulting work for Bayer.
Vet the virtual clinic before you hand over a credit card.
If your province doesn't cover MHT and you're looking at Felix, Phoenix, Rouge, Midi, Alloy or Evernow, our eleven-question virtual care checklist is the screening tool. Use it before you book.
